News

Lower respiratory diseases including chronic obstructive pulmonary disease (COPD) were the sixth leading cause of death in the U.S. in 2022, accounting for 4.5% of all deaths registered that year. That’s according to a report, “Deaths: Leading Causes for 2022,” released by the U.S. Centers for Disease Control and…

A urine test developed in a dipstick format by Global Access Diagnostics helped not only distinguish between stable and exacerbation states among chronic obstructive pulmonary disease (COPD) patients but also was able to predict exacerbations a week in advance. That’s according to the results of a new study…

Oral supplementation with nicotinamide riboside, a form of vitamin B3, helped reduce markers of lung inflammation in older adults with chronic obstructive pulmonary disease (COPD), data from a placebo-controlled study shows. The benefits were sustained for at least three months after supplementation ended. These findings are “significant, because inflammation…

The U.S. Food and Drug Administration (FDA) has approved Abrysvo, a vaccine that protects against lung infections caused by the respiratory syncytial virus — commonly known as RSV — for adults as young as 18 with chronic obstructive pulmonary disease (COPD) or other conditions that increase the risk of…

The U.S. Food and Drug Administration has cleared the start of clinical trial testing of KT-621, Kymera Therapeutics’ oral therapy for chronic obstructive pulmonary disease (COPD) and other diseases marked by type 2 inflammation. KT-621 is designed to target STAT6, a protein involved in type 2 inflammation, which…

Ohtuvayre (ensifentrine), an inhaled therapy approved in the U.S. earlier this year for adults with chronic obstructive pulmonary disease (COPD), has been found to safely and effectively lead to clinical improvements among COPD patients regardless of disease severity, smoking history, and chronic bronchitis history. Chronic bronchitis is a…

Dry-powder corticosteroid inhalers, or those designed to have a low impact on climate, are as effective as those based on pressurized, metered doses at reducing the risk of poor outcomes in people with both chronic obstructive pulmonary disease (COPD) and asthma. A large study in Denmark found the two…

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils. Elevated eosinophils are a marker of type 2 inflammation, which is thought to contribute…

The voice of people with chronic obstructive pulmonary disease (COPD) becomes more pitched and sounds breathy or hoarse at the early stages of disease exacerbations, which are episodes when symptoms suddenly worsen, according to a pilot study where 28 patients were asked to record their voices every day for…

Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation, which contributes to lung inflammation. That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK…